Alligator Biosciencehas appointed Theradex Oncology as CRO for their planned phase I study of ATOR-1015 for the treatment of metastatic cancer.

The upcoming clinical phase I study with ATOR-1015 is a first-in-human dose escalation study in patients with metastatic cancer. The study will be conducted at five sites in Sweden and Denmark.

“Engaging Theradex is a key step towards starting our clinical phase I study with ATOR-1015 later this year”, said Per Norlén, CEO of Alligator Bioscience. “We have worked previously with Theradex on the ADC-1013 clinical phase I trial and, based on their robust delivery and extensive expertise in clinical oncology research, we are confident in their ability to assist us in executing high-quality studies and we look forward to continuing our successful collaboration”.

The study is expected to commence in the second half of 2018.

Photo of Per Norlén: Jenny Leyman